Volume and value of payments by company interests in 2020
| PO type | Company’s interest | Volume; n (%) | Value: £ |
| Overall* | Definitely yes | 678 (48) | £12 529 514 (56%) |
| Probably yes | 525 (37) | £7 700 069 (34%) | |
| No† | 219 (15) | £2 347 732 (10%) | |
| Rare | Definitely yes | 161 (56) | £3 119 217 (67%) |
| Probably yes | 115 (40) | £1 388 545 (30%) | |
| No† | 10 (4) | £122 017 (3%) | |
| Non-rare | Definitely yes | 517 (54) | £9 410 297 (59%) |
| Probably yes | 389 (41) | £6 056 915 (38%) | |
| No† | 46 (5) | £408 449 (3%) |
Notes: Definitely yes indicates payments directed to patient organisations that operated in a disease area (ICD-11 level 4 or higher) for which the company has a product in its portfolio or pipeline. Probably yes indicates directed to patient organisations that operated in a disease area (ICD-11 level 3 or lower) for which the company has a product in its portfolio or pipeline. No refers to directed to patient organisations that operated in a disease area for which no link could be found to the company’s portfolio or pipeline.The higher the ICD-11, the more specific the condition. For example, if the ICD-11 level 4 is plasma cell neoplasms, level 2 would be neoplasms of haematopoietic or lymphoid tissues. Further details on how this variable was constructed can be found in the online supplemental material
*Please note that the overall results are not a sum of the rare and non-rare results, as they also include patient organisations that could not be classified in either group and are non-disease-specific.
†Please note that the no category of interest conservatively includes also interests that were considered as unclear.
ICD-11, International Classification of Diseases V.11 ; PO, patient organisations.